MX355041B - Dominios de union a albumina consenso no naturales. - Google Patents

Dominios de union a albumina consenso no naturales.

Info

Publication number
MX355041B
MX355041B MX2014014384A MX2014014384A MX355041B MX 355041 B MX355041 B MX 355041B MX 2014014384 A MX2014014384 A MX 2014014384A MX 2014014384 A MX2014014384 A MX 2014014384A MX 355041 B MX355041 B MX 355041B
Authority
MX
Mexico
Prior art keywords
binding domains
albumin binding
natural consensus
consensus albumin
natural
Prior art date
Application number
MX2014014384A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014384A (es
Inventor
Steven Jacobs
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2014014384A publication Critical patent/MX2014014384A/es
Publication of MX355041B publication Critical patent/MX355041B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2014014384A 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales. MX355041B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US201361776918P 2013-03-12 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
MX2014014384A MX2014014384A (es) 2015-05-11
MX355041B true MX355041B (es) 2018-03-28

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014384A MX355041B (es) 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales.

Country Status (15)

Country Link
US (3) US9156887B2 (enrdf_load_stackoverflow)
EP (1) EP2855509B1 (enrdf_load_stackoverflow)
JP (3) JP2015519345A (enrdf_load_stackoverflow)
KR (1) KR102053674B1 (enrdf_load_stackoverflow)
CN (1) CN104470944B (enrdf_load_stackoverflow)
AU (2) AU2013266215B2 (enrdf_load_stackoverflow)
BR (1) BR112014029409B1 (enrdf_load_stackoverflow)
CA (1) CA2874646C (enrdf_load_stackoverflow)
DK (1) DK2855509T3 (enrdf_load_stackoverflow)
EA (1) EA036487B1 (enrdf_load_stackoverflow)
ES (1) ES2670442T3 (enrdf_load_stackoverflow)
IL (2) IL235808A (enrdf_load_stackoverflow)
MX (1) MX355041B (enrdf_load_stackoverflow)
PT (1) PT2855509T (enrdf_load_stackoverflow)
WO (1) WO2013177398A2 (enrdf_load_stackoverflow)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
AU2014229549B2 (en) * 2013-03-14 2018-11-01 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
HK1245814B (en) * 2015-04-29 2020-06-19 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
US10456442B2 (en) * 2015-06-18 2019-10-29 Albert Einstein College Of Medicine FGF receptor ligands for treating diabetes and obesity
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
EP3423480A1 (en) 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3932432A1 (en) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体
WO2019032952A1 (en) 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
WO2019175176A1 (en) 2018-03-13 2019-09-19 Affibody Ab Polypeptides based on a novel scaffold
KR102282240B1 (ko) 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
JP7703541B2 (ja) * 2019-12-18 2025-07-07 アロ・バイオセラピューティクス・カンパニー 血清アルブミン結合性フィブロネクチンiii型ドメインおよびその使用
US12123036B2 (en) 2020-02-26 2024-10-22 Northwestern University Soluble ACE2 variants and uses therefor
KR102601875B1 (ko) * 2020-03-25 2023-11-14 (주)큐리진 면역 회피성 항종양 아데노바이러스
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
KR20240034160A (ko) 2021-04-14 2024-03-13 에이알오 바이오테라퓨틱스 컴패니 Cd71 결합 피브로넥틴 3형 도메인
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제
AU2023395989A1 (en) 2022-12-16 2025-07-24 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
ATE198768T1 (de) * 1992-05-07 2001-02-15 Affitech As Von l protein abgeleitete immunoglobulin-bindende proteine und deren anwendungen
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
CN102007147B (zh) 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
US8278419B2 (en) * 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US8580274B2 (en) * 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
AU2011239706B2 (en) 2010-04-13 2015-08-20 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
EP3103478B1 (en) * 2010-04-30 2019-04-17 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
BR112014029409A2 (enrdf_load_stackoverflow) 2017-08-15
IL235808A (en) 2017-10-31
DK2855509T3 (en) 2018-07-23
CN104470944B (zh) 2021-09-14
US20180009854A1 (en) 2018-01-11
IL254652B (en) 2019-12-31
IL254652A0 (en) 2017-11-30
WO2013177398A3 (en) 2014-03-27
HK1209134A1 (en) 2016-03-24
KR102053674B1 (ko) 2019-12-09
AU2013266215B2 (en) 2017-12-07
US20130316952A1 (en) 2013-11-28
US10280200B2 (en) 2019-05-07
WO2013177398A2 (en) 2013-11-28
EA201590136A1 (ru) 2016-02-29
EP2855509B1 (en) 2018-05-02
AU2017261625B2 (en) 2019-11-21
CA2874646A1 (en) 2013-11-28
BR112014029409B1 (pt) 2022-11-29
JP2018171063A (ja) 2018-11-08
US9156887B2 (en) 2015-10-13
EP2855509A2 (en) 2015-04-08
JP2021019595A (ja) 2021-02-18
US20160083436A1 (en) 2016-03-24
EA036487B1 (ru) 2020-11-16
PT2855509T (pt) 2018-08-03
IL235808A0 (en) 2015-01-29
MX2014014384A (es) 2015-05-11
AU2017261625A1 (en) 2017-12-07
EP2855509A4 (en) 2016-01-13
CA2874646C (en) 2020-12-01
AU2013266215A1 (en) 2014-12-04
JP7166081B2 (ja) 2022-11-07
JP2015519345A (ja) 2015-07-09
ES2670442T3 (es) 2018-05-30
CN104470944A (zh) 2015-03-25
KR20150016585A (ko) 2015-02-12

Similar Documents

Publication Publication Date Title
AU2017261625B2 (en) Non-natural consensus albumin binding domains
PH12014501736A1 (en) Therapeutic use of p75ntr neurotrophin binding protein
DK3791896T5 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
NZ707086A (en) Anti-cd40 antibodies and methods of use
AU2011328009A8 (en) Compounds and methods for treating pain
PH12013501636A1 (en) Treatment of osteoarthritis and pain
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
NZ709059A (en) Immunotherapy with binding agents
PH12014502274A1 (en) Anti-fcrn antibodies
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
PL2888359T3 (pl) Białka fuzyjne i sposoby leczenia, zapobiegania lub łagodzenia bólu
MX2019003619A (es) Formulaciones de bromocriptina.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EA201391171A1 (ru) Формы рифаксимина и их применение
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
NZ727446A (en) Therapeutic use of p75ntr neurotrophin binding protein
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
SA113340398B1 (ar) استخدام (s-(rs- سيكلوبروبيل-s-(4-{[4-{[(1r, 2r)-2- هيدروكسي-1- ميثيل بروبيل] أوكسي}-5-(تراي فلوروميثيل) بيريميدين-2- يل] أمينو} فنيل) سلفوكسيميد من أجل علاج أورام معينة
WO2013053034A3 (pt) Tiazacridinas utilizadas na terapia anticâncer

Legal Events

Date Code Title Description
FG Grant or registration